EMA First-In-Human Trial Proposals Focus On Dosing, Non-Clinical Data, Study Design

The European Medicines Agency has put out for consultation a draft revised guideline intended to minimize the risks involved with running first-in-human and other early clinical trials, taking into account the lessons learnt from the French Phase I trial tragedy at the beginning of 2016.